ORLANDO—The dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin, which is approved for the treatment of adult patients with type 2 diabetes, may benefit adult type 1 diabetics, investigators announced at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA).

“It’s important to emphasize that this was a small pilot study but nonetheless the first ever to test the use of a DPP-4 inhibitor for type 1 diabetes,” Satish Garg, MD, professor of medicine and pediatrics at the University of Colorado in Denver, commented.

For the trial, 20 inadequately controlled type 1 patients were randomized to four weeks’ treatment with sitagliptin 100 mg daily or placebo and then switched to the alternate treatment for four weeks. 

Continue Reading

Sitagliptin treatment produced a significant reduction in mean blood glucose of about 12 mg/dL, leading to a significant hemoglobin A1C reduction of 0.27%.   There was also a “near 10%” significant reduction in insulin dose during sitagliptin treatment. 

 Dr. Garg plans to follow-up his single-center pilot study with a four-month multicenter study enrolling 120 type 1 patients.